🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leeds
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leeds

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca27 Janssen Research & Development, LLC14 BeOne Medicines9 AbbVie9 Bristol-Myers Squibb9
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
316 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3
270
Glasgow, Leeds, London, Manchester, Nottingham
2021-02-23
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Cambridge, Colchester, Leeds, Nottingham, Surrey
2021-01-28
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
BioNTech SE
Phase 2/3
358
Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2021-01-07
Active, closed
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308Primary Sclerosing Cholangitis
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 2
220
Glasgow, Leeds
2020-12-18
Active, closed
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04794101X-Linked Retinitis Pigmentosa
Janssen Research & Development, LLC
Phase 3
97
Edinburgh, Glasgow, Leeds, London
2020-12-04
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Daiichi Sankyo
Phase 3
1,600
Peterborough, Maidstone, Manchester, Metropolitan Borough of Wirral, Nottingham, Bath, Taunton, Leeds
2020-12-04
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497IgG4 Related Disease
Amgen
Phase 3
135
Leeds, London, Newcastle, Oxford
2020-12-04
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
210
Leeds, London
2020-10-08
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood
2020-07-24
Active, closed
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
Sarepta Therapeutics, Inc.
Phase 3
160
Leeds, Birmingham, London
2020-07-13
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
870
Sheffield, London, London-Camden, Southampton, Leeds, Manchester
2020-07-06
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
Sapience Therapeutics
Phase 1/2
125
Edinburgh, Glasgow, Leeds, London
2020-07-01
Active, closed
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
NCT04277637Mature B-Cell Malignancies
BeOne Medicines
Phase 1
437
Leeds
2020-03-24
Active, closed
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
NCT04170283B-cell Malignancies
BeOne Medicines
Phase 3
955
Aberdeen, Birmingham, Bournemouth, Canterbury, Glasgow, Greater Manchester, Headington, Leeds
2020-01-16
Recruiting
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
NCT03969329Secondary Hyperparathyroidism
Amgen
Phase 3
24
Glasgow, Leeds, London, Southampton
2019-12-20
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
BicycleTx Limited
Phase 1/2
288
London, Manchester, Cambridge, Leeds, Newcastle upon Tyne
2019-11-07
Active, closed
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
Scancell Ltd
Phase 2
173
Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford
2019-08-19
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene
Phase 3
665
Aberdeen, Leeds, London, Oxford, Sutton in Ashfield
2019-08-12
Recruiting
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
NCT04029363Mitral Regurgitation
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
NCT03709680Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
Pfizer
Phase 2
128
Newcastle upon Tyne, Glasgow, Leeds, London
2019-05-24
Recruiting
Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator
NCT03876054Chronic Pain
Abbott Medical Devices
Observational
2,000
Norwich, Liverpool, Bristol, Leeds
2019-03-13
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
AstraZeneca
Phase 1/2
50
Leeds, London, Sutton
2019-03-07
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
724
Birmingham, Leeds, London, Manchester
2019-03-06
Rows per page Showing 251–275 of 316
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leeds

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.